New pompe drug trial aims for safer treatment
NCT ID NCT07354724
First seen Jan 25, 2026 · Last updated May 18, 2026 · Updated 12 times
Summary
This early-stage trial tests a new drug called DNL952 in 32 adults with late-onset Pompe disease. The main goal is to check safety and how the body processes the drug. Participants include those currently on enzyme therapy and those who haven't had treatment in the past year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LATE ONSET POMPE DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Lysosomal & Rare Disorders Research & Treatment Center
RECRUITINGFairfax, Virginia, 22030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.